Hinge Health Inc. $HNGE Stake Raised by Schwartz Investment Counsel Inc.

Schwartz Investment Counsel Inc. lifted its stake in Hinge Health Inc. (NYSE:HNGE) by 28.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 59,000 shares of the company’s stock after purchasing an additional 13,000 shares during the quarter. Schwartz Investment Counsel Inc.’s holdings in Hinge Health were worth $2,275,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its holdings in shares of Hinge Health by 162.7% during the fourth quarter. BNP Paribas Financial Markets now owns 727,672 shares of the company’s stock worth $33,800,000 after acquiring an additional 450,643 shares in the last quarter. UBS Group AG grew its stake in Hinge Health by 168.8% in the fourth quarter. UBS Group AG now owns 356,701 shares of the company’s stock valued at $16,569,000 after purchasing an additional 223,980 shares in the last quarter. Tudor Investment Corp ET AL increased its position in Hinge Health by 25.9% in the 3rd quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company’s stock worth $18,467,000 after purchasing an additional 77,464 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Hinge Health by 755.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company’s stock worth $1,271,000 after purchasing an additional 24,155 shares in the last quarter. Finally, Alkeon Capital Management LLC increased its holdings in Hinge Health by 110.4% in the fourth quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company’s stock worth $36,747,000 after buying an additional 415,093 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Canaccord Genuity Group increased their price objective on Hinge Health from $65.00 to $76.00 and gave the company a “buy” rating in a report on Monday, June 15th. Wall Street Zen lowered Hinge Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Citizens Jmp increased their price objective on shares of Hinge Health from $65.00 to $80.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. KeyCorp increased their price objective on Hinge Health from $90.00 to $125.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Raymond James Financial increased their price target on Hinge Health from $70.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.67.

Insider Buying and Selling at Hinge Health

In other Hinge Health news, CEO Daniel Antonio Perez sold 104,544 shares of Hinge Health stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $55.09, for a total value of $5,759,328.96. Following the completion of the sale, the chief executive officer owned 35,470 shares in the company, valued at $1,954,042.30. The trade was a 74.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $60.22, for a total value of $5,018,373.48. Following the sale, the chairman owned 83,334 shares of the company’s stock, valued at approximately $5,018,373.48. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,954,433 shares of company stock valued at $300,724,532 in the last ninety days. 18.92% of the stock is currently owned by corporate insiders.

Hinge Health Price Performance

Shares of Hinge Health stock opened at $90.03 on Tuesday. The firm has a market cap of $6.97 billion, a price-to-earnings ratio of -7.30 and a beta of 1.13. Hinge Health Inc. has a one year low of $30.08 and a one year high of $91.50. The stock’s 50-day moving average is $66.28 and its 200-day moving average is $50.48.

Hinge Health (NYSE:HNGE) last released its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.33. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The business had revenue of $182.31 million during the quarter. During the same period in the prior year, the business posted $1.30 earnings per share. Hinge Health’s quarterly revenue was up 47.2% compared to the same quarter last year. On average, equities analysts expect that Hinge Health Inc. will post 1.33 EPS for the current year.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.